Patient Controlled Analgesia Set to Go Mainstream

(openPR) (Amherst, NH) - An increasing understanding of the physiology of pain coupled with patient-friendly dosage forms and delivery techniques is providing caregivers and prescribers with improved tools for helping patient manage their own pain. New and emerging pain delivery products that allow patients to play an active role in the timing and dosing of their pain medication allow patients to balance pain relief and medication side effects, and potentially improve quality-of-life.

Pain management philosophy is based on the premise of treating pain early and aggressively. This is based on research that pain is tightly correlated with decreased quality of life, and increased incidence of anxiety and depression. It is now understood that pain causes the physiologic release of destructive enzymes that can damage even healthy tissue. The aging population – particularly in North America and Western Europe, where the quality of medical care is high and consumers enjoy a relatively high standard of living – will create a growing market of mature and elderly needing drug therapies and pain management for a variety of maladies associated with the aging process. These factors are attracting well-financed players and elevating alliance activity in this sector.

Greystone’s analysis of the commercial market for patient controlled analgesia is summarized in a new and comprehensive report. Patient Controlled Analgesia: Products, Markets, Players and Outlook includes analysis of the current global PCA market, assessments of pipeline drug-device combination products for PCA, an examination of the dynamics of patient care that will affect market development, profiles of companies active in the PCA segment, and market data and forecasts.

More information is available at www.greystoneassociates.org .



Source: Greystone Research Associates